Trigger AI
RXST
RxSight, Inc. Common Stock
$4.88-$0.01(-0.31%)
- RVOL0.49x
- float38.58M
- SI+10.46%
- CTB0.3%
Catalyst
RxSight Schedules Third Quarter 2026 Financial Results Conference Call
Trigger AI (analysis)
RxSight announced that it will report its financial results for the third quarter of 2026 after the market close on November 3, 2026, accompanied by a management conference call. This announcement is a routine corporate schedule notification that does not alter the company's current business or financial position prior to the actual release of earnings data. While cash on hand covers about 5 months of operating costs, highlighting ongoing attention to cash management and financial performance, this advance notice of an upcoming earnings report represents a routine event with limited immediate economic impact.
B · RXST · GlobeNewswire · Published
AI analysis. Not investment advice.
Original
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 8782462. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/ . An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The Light Adjustable Lens™ system, comprised of the RxSight Light Adjustable Lens™ products (LAL™ and LAL+™), RxSight Light Delivery Device™ (LDD™), and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com . Investor Relations Contact: Oliver Moravcevic VP, Investor Relations omoravcevic@rxsight.com
Original source